Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 13
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment.
Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, Medina Sanchez L, Rana M, Richie TG, Mims TS, Gocher-Demske AM, Cervantes-Barragan L, Mullett SJ, Gelhaus SL, Bruno TC, Cannon N, McCulloch JA, Vignali DAA, Hinterleitner R, Joglekar AV, Pierre JF, Lee STM, Davar D, Zarour HM, Meisel M. Bender MJ, et al. Cell. 2023 Apr 27;186(9):1846-1862.e26. doi: 10.1016/j.cell.2023.03.011. Epub 2023 Apr 6. Cell. 2023. PMID: 37028428 Free PMC article.
Therapeutic targeting of regulatory T cells in cancer.
Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali DAA. Shan F, et al. Trends Cancer. 2022 Nov;8(11):944-961. doi: 10.1016/j.trecan.2022.06.008. Epub 2022 Jul 16. Trends Cancer. 2022. PMID: 35853825 Free PMC article. Review.
Targeting Cbl-b in cancer immunotherapy.
Augustin RC, Bao R, Luke JJ. Augustin RC, et al. J Immunother Cancer. 2023 Feb;11(2):e006007. doi: 10.1136/jitc-2022-006007. J Immunother Cancer. 2023. PMID: 36750253 Free PMC article. Review.
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, Balaji AK, Vetizou M, Prescott SM, Fernandes MR, Costa RGF, Yuan W, Salcedo R, Bahadiroglu E, Roy S, DeBlasio RN, Morrison RM, Chauvin JM, Ding Q, Zidi B, Lowin A, Chakka S, Gao W, Pagliano O, Ernst SJ, Rose A, Newman NK, Morgun A, Zarour HM, Trinchieri G, Dzutsev AK. McCulloch JA, et al. Nat Med. 2022 Mar;28(3):545-556. doi: 10.1038/s41591-022-01698-2. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228752 Free PMC article.
Myeloid Maturity: ATRA to Enhance Anti-PD-1?
Olson DJ, Luke JJ. Olson DJ, et al. Clin Cancer Res. 2023 Apr 3;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652. Clin Cancer Res. 2023. PMID: 36656164 Free PMC article.
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma.
Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ. Pourmaleki M, et al. Cancer Immunol Res. 2022 Mar 1;10(3):303-313. doi: 10.1158/2326-6066.CIR-21-1083. Cancer Immunol Res. 2022. PMID: 35013003 Free PMC article.
36 results